AU5259296A - Flavones and coumarins as agents for the treatment of athero sclerosis - Google Patents

Flavones and coumarins as agents for the treatment of athero sclerosis

Info

Publication number
AU5259296A
AU5259296A AU52592/96A AU5259296A AU5259296A AU 5259296 A AU5259296 A AU 5259296A AU 52592/96 A AU52592/96 A AU 52592/96A AU 5259296 A AU5259296 A AU 5259296A AU 5259296 A AU5259296 A AU 5259296A
Authority
AU
Australia
Prior art keywords
coumarins
flavones
agents
treatment
athero sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52592/96A
Inventor
Uday Saxena
Bharat Kalidas Trivedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU5259296A publication Critical patent/AU5259296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU52592/96A 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of athero sclerosis Abandoned AU5259296A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41870995A 1995-04-07 1995-04-07
US418709 1995-04-07
PCT/US1996/004028 WO1996031206A2 (en) 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
AU5259296A true AU5259296A (en) 1996-10-23

Family

ID=23659261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52592/96A Abandoned AU5259296A (en) 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of athero sclerosis

Country Status (2)

Country Link
AU (1) AU5259296A (en)
WO (1) WO1996031206A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160279A (en) * 2022-07-27 2022-10-11 中国药科大学 Benzopyrone compound, pharmaceutical composition and application

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1009404A4 (en) * 1997-05-13 2009-07-01 Octamer Inc METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US5922719A (en) * 1997-08-11 1999-07-13 Warner-Lambert Company Coumarin dopamine D4 receptor antagonists
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
CA2328962A1 (en) * 1998-04-17 1999-10-28 Parker Hughes Institute Btk inhibitors and methods for their identification and use
FR2781153B1 (en) * 1998-07-15 2001-08-03 Lafon Labor FLAVONOID-BASED THERAPEUTIC COMPOSITION FOR USE IN THE TREATMENT OF TUMORS WITH CYTOTOXIC AGENTS
DE19845372A1 (en) * 1998-10-02 2000-04-20 Gruenenthal Gmbh Use of catechol derivatives as proteinase inhibitors
WO2000035435A1 (en) * 1998-12-15 2000-06-22 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000050030A1 (en) * 1999-02-25 2000-08-31 Ted Ebendal New use
WO2002008217A2 (en) * 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
JP4256679B2 (en) * 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド How to treat restenosis
KR20020096368A (en) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 Mass cell production method of chondrocytes by the inhibition of de-differentiation and a method for screening it
KR20020096367A (en) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 Pharmaceutical composition for the prevention and treatment of arthritis having effect of essential treatment and a method for screening it
AR038136A1 (en) 2002-01-24 2004-12-29 Merck Frosst Canada Inc CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
JP4587652B2 (en) * 2002-09-09 2010-11-24 株式会社フラバミン Novel flavonoid compounds and their use
CA2497560A1 (en) 2002-09-20 2004-04-01 Promega Corporation Luminescence-based methods and probes for measuring cytochrome p450 activity
US8138165B2 (en) * 2002-10-22 2012-03-20 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
JP2006511500A (en) 2002-10-30 2006-04-06 メルク　エンド　カムパニー　インコーポレーテッド γ-Aminoamide-based chemokine receptor activity modulator
US20060252707A1 (en) * 2003-05-28 2006-11-09 Universite De Liege Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin
WO2005101838A2 (en) 2004-04-13 2005-10-27 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
EP1885875B1 (en) 2005-05-31 2019-05-22 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
WO2007010342A1 (en) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
US8410109B2 (en) * 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
MEP1008A (en) 2005-12-21 2010-02-10 Incyte Corp 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CN1837202B (en) * 2006-04-25 2010-08-18 中国人民解放军第二军医大学 Flavonols with blood-fat-lowering effect
MX2009008099A (en) 2007-02-01 2009-12-14 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases.
WO2009118338A2 (en) * 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of a polyphenolic type compound for preventing or treating a polyglutamine expansion neurodegenerative disease
KR101629356B1 (en) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 Methods of preparing quinazolinone derivatives
JP5597200B2 (en) 2008-08-18 2014-10-01 プロメガ コーポレイション Compounds producing luminescence and methods for detecting cytochrome P4503A enzyme
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
CN102227420B (en) * 2008-09-29 2015-06-24 西特里斯药业公司 Quinazolinone, quinolone and related analogs as sirtuin modulators
EP2344877A4 (en) 2008-09-30 2014-09-10 Univ Case Western Reserve MOLECULAR PROBES FOR MYELIN IMAGING
GEP20146064B (en) 2008-11-26 2014-03-25 Pfizer 3-minocyclopentanecarboxamides as chemokine receptor modulators
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CA2748943A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
EP2492267B1 (en) 2009-02-24 2014-11-26 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient
KR101913109B1 (en) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
DK2421533T3 (en) 2009-04-22 2019-01-07 Resverlogix Corp Hitherto unknown anti-inflammatory agents
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
ES2635030T3 (en) 2010-12-23 2017-10-02 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as modulators of the CRTH2 receptor
BR112013028430A2 (en) 2011-05-04 2017-08-01 Merck Sharp & Dohme compound, pharmaceutical composition, method for treating a spleen tyrosine kinase (syk) mediated disease or condition, and use of a therapeutically efficient amount of the compound
CN102274237B (en) * 2011-06-16 2012-12-05 成都中医药大学 New uses of flavonoids
WO2012174176A1 (en) 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
LT2773354T (en) 2011-11-01 2019-08-12 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
EP3099683B1 (en) 2014-01-29 2020-08-05 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
WO2016123141A1 (en) * 2015-01-26 2016-08-04 Berreau Lisa M Carbon monoxide releasing molecules and associated methods
GB2540234B (en) 2015-02-19 2020-12-02 Council Scient Ind Res An antioxidant compound having anti atherosclerotic effect and preparation thereof
JP6903585B2 (en) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション Compositions and Therapeutic Methods for the Treatment of Complement-Related Diseases
KR101837690B1 (en) * 2016-04-04 2018-03-13 한국한의학연구원 Compostion for prevention or treatment restenosis comprising Alpinia officinarum Hance extracts, fractions or galangin seperated from therefrom
DE102016223763A1 (en) * 2016-11-30 2018-05-30 Beiersdorf Ag Use of 2'-methoxyflavone in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin
CN109265424B (en) * 2018-09-25 2020-08-21 天津中医药大学 Flavonoid derivative and preparation method and identification method thereof
WO2020143793A1 (en) 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 Salts of heterocyclic compound and use thereof
CN117304154A (en) * 2023-09-26 2023-12-29 上海上药第一生化药业有限公司 A kind of preparation method of dimethylphrine analog
CN117304156A (en) * 2023-09-26 2023-12-29 上海上药第一生化药业有限公司 A dimethylphen analog and its refining method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6928M (en) * 1967-11-24 1969-05-05
FR2244493A1 (en) * 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE3601417A1 (en) * 1986-01-20 1987-07-23 Nattermann A & Cie 2'-Alkyl(alkenyl)-substituted quercetins
EP0347864A3 (en) * 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Anti-atherogenic agents
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
FR2689127B1 (en) * 1992-03-31 1994-05-06 Adir Cie NEWS 3 ', 5' -DITERTBUTYL-4'-HYDROXY FLAVONES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JPH0725761A (en) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd Cartilage protectant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160279A (en) * 2022-07-27 2022-10-11 中国药科大学 Benzopyrone compound, pharmaceutical composition and application
CN115160279B (en) * 2022-07-27 2023-11-24 中国药科大学 Benzopyrone compounds, pharmaceutical compositions and uses

Also Published As

Publication number Publication date
WO1996031206A2 (en) 1996-10-10
WO1996031206A3 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
AU5259296A (en) Flavones and coumarins as agents for the treatment of athero sclerosis
AU5750796A (en) System for the treatment of insomnia
AU5740496A (en) Micromechanical device and method for enhancing delivery of compounds through the skin
AU7443496A (en) Treatment of migraine
EP0711029A3 (en) Microstructure and method of forming the same
ZA965088B (en) Methods of preventing or treating allergles
ZA966240B (en) Methods for treatment of allergic asthma.
AU9040491A (en) Method for the isolation and purification of taxane derivatives
AU5886196A (en) Novel benzopyran compounds and methods for their use
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU2672795A (en) Benzopyrans and their use as therapeutic agents
AU4774597A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
AU1556497A (en) Agents for the treatment and prevention of aids
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
HUP0002938A3 (en) Procedure and system for the setting up of calls
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
PL321711A1 (en) Methods of and compositions for controlling the cd28 expression
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU5699396A (en) Compositions for the treatment of skin conditions
AU4604697A (en) Compositions and methods for the treatment of human cytomegalovirus infection
ZA969315B (en) Processes and intermediates for the preparation of ziprasidone.
AU6786798A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
IL117191A0 (en) Process for the preparation of oxazolidinones and their use
AU4941796A (en) Use of moxonidine for the treatment of atherosclerosis